Figure: Effect of hAb21 mAb on tumor growth in knock-in mice expressing human PD-1 （Human PD-1 gene knock-in mice were inoculated with 1x106 syngeneic MC38 tumor cells. When tumors reached 50 mm3 in size，mice were randomized into 3 groups. Intra-peritoneal (i.p) injections with 200 ug mAb (pembrolizumab or hAb21) or saline were given on days 6, 10, 13 and 17 after inoculation. A: Tumor growth in early-stage; B: Tumor growth in both early- and later-stage）._Stainwei_large image_Download

Caption	Figure: Effect of hAb21 mAb on tumor growth in knock-in mice expressing human PD-1 （Human PD-1 gene knock-in mice were inoculated with 1x106 syngeneic MC38 tumor cells. When tumors reached 50 mm3 in size，mice were randomized into 3 groups. Intra-peritoneal (i.p) injections with 200 ug mAb (pembrolizumab or hAb21) or saline were given on days 6, 10, 13 and 17 after inoculation. A: Tumor growth in early-stage; B: Tumor growth in both early- and later-stage）.
Source	Stainwei
Other pictures
Download
Related Press Releases Links	Stainwei Granted US Patent for anti-VEGF Monoclonal Antibody and its anti-PD-1 mAb demonstrating prolonged anti-tumor activity in pre-clinical studies 思坦維VEGF單抗獲美國專利；PD-1單抗在人源化鼠中抗腫瘤持久顯著 Stainwei, 전임상 연구에서 지속적인 항종양 활성이 입증된 항VEGF 단일클론항체 및 항PD-1 단일클론항체 미국 특허 획득 Stainweiが抗VEGFモノクローナル抗体の米国特許の許可を取得 Stainweiが抗VEGFモノクローナル抗体の米国特許の許可を取得